United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block and myocardial damage.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. parenteral administration of the drug is contraindi

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 80 mg in 1 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 100 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

exela pharma sciences, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 50 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

Australia - English - Department of Health (Therapeutic Goods Administration)

caruso's natural health pty ltd - magnesium amino acid chelate, quantity: 50 mg (equivalent: magnesium, qty 10 mg); magnesium phosphate pentahydrate, quantity: 508.23 mg (equivalent: magnesium, qty 105 mg); magnesium citrate, quantity: 123.76 mg (equivalent: magnesium, qty 20 mg); magnesium orotate, quantity: 156.25 mg (equivalent: magnesium, qty 10 mg); magnesium aspartate dihydrate, quantity: 66.67 mg (equivalent: magnesium, qty 5 mg); heavy magnesium oxide, quantity: 259.11 mg (equivalent: magnesium, qty 150 mg) - tablet, modified release - excipient ingredients: colloidal anhydrous silica; hypromellose; titanium dioxide; povidone; magnesium stearate; microcrystalline cellulose; carnauba wax; croscarmellose sodium; macrogol 400; hydrogenated vegetable oil; calcium hydrogen phosphate dihydrate - temporarily relieve mild fluid retention ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; decrease/reduce/relieve muscle cramps ; helps reduce occurrence of muscle cramp ; helps decrease/reduce/relieve mild muscle spasms/twitches ; maintain/support healthy muscle contraction function ; maintain/support muscle health ; maintain/support muscle function ; maintain/support muscle relaxation ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support (state vitamin/mineral) within normal range ; support healthy stress response in the body ; maintain/support nervous system health ; maintain/support nervous system function ; decrease/reduce/relieve menstrual spasms/cramps ; decrease/reduce/relieve mood changes/mood swings associated with premenstrual tension ; decrease/reduce/relieve breast pain/tenderness associated with premenstrual tension ; decrease/reduce/relieve symptoms of premenstrual tension

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - magnesium - granules for oral solution - 5 millimole(s) - magnesium aspartate

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's origins professional formulas - viburnum opulus, quantity: 62.5 mg (equivalent: viburnum opulus, qty 250 mg); magnesium orotate, quantity: 98.46 mg (equivalent: magnesium, qty 6.4 mg); magnesium citrate, quantity: 103 mg (equivalent: magnesium, qty 16 mg); calcium hydrogen phosphate dihydrate, quantity: 250 mg (equivalent: calcium, qty 58.2 mg); magnesium amino acid chelate, quantity: 888 mg (equivalent: magnesium, qty 177.6 mg); taurine, quantity: 50 mg - tablet, film coated - excipient ingredients: silicon dioxide; crospovidone; maltodextrin; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; povidone; titanium dioxide; purified talc; triethyl citrate; sodium lauryl sulfate; methacrylic acid copolymer; sodium bicarbonate; indigo carmine aluminium lake; sunset yellow fcf aluminium lake; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - maintain/support energy levels ; maintain/support general health and wellbeing ; maintain/support bone strength ; maintain/support muscle health ; maintain/support muscle function ; aid/assist/helps in the management of muscle sprain/strain ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support neuromuscular function